The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has appointed Bhavin Mukund Mehta, Wholetime Director of Kilitch Drugs (India) Ltd, as its new Vice-Chairman. This prestigious appointment recognizes his vast experience and contributions to India's pharmaceutical industry and export sector.

With over 25 years of industry expertise, Bhavin Mehta has played a pivotal role in expanding Kilitch Drugs' footprint in international markets while strengthening its domestic presence. His leadership in business development, strategy management, international marketing, and operations makes him an ideal choice to drive Pharmexcil’s vision of promoting Indian pharmaceuticals on a global scale.

A Leader in Pharmaceutical Exports

Pharmexcil, established by the Ministry of Commerce and Industry, Government of India, is responsible for promoting India's pharmaceutical exports. The council provides market insights, regulatory support, and helps Indian companies participate in international trade fairs and exhibitions. Since its formation in 2004, Pharmexcil has significantly contributed to making India a top exporter of generic medicines worldwide.

Bhavin Mehta has been actively involved with Pharmexcil for years. In 2012, he was appointed as Chairman of the Exhibition Committee, where he played a key role in launching IPHEX, India's largest exhibition to promote pharmaceutical exports. His vision and leadership have helped shape India’s presence in global pharmaceutical markets.

Commenting on his appointment, Bhavin Mukund Mehta expressed his gratitude:

"I am truly honored to be appointed as Vice-Chairman at Pharmexcil. While promoting the growth of pharmaceutical exports, I am also committed to supporting MSMEs in India’s pharma sector. These enterprises play a vital role in enhancing global healthcare. Together, we will work to unlock new opportunities, drive innovation, and strengthen India’s position as a leader in pharmaceutical exports."

About Kilitch Drugs (India) Ltd

Founded in 1978, Kilitch Drugs (India) Ltd is a prominent pharmaceutical manufacturing company with operations in India, Ethiopia, and a new greenfield project in Maharashtra. The company specializes in injectables, ophthalmic products, oral solid dosages (OSD), and nutraceuticals. Its manufacturing facilities comply with stringent regulatory standards, including WHO-GMP, ISO 9001, ISO 13485, and certifications from Kenya, Nigeria, Ghana, Sudan, the Philippines, Ethiopia, and other global regulatory authorities.

Kilitch Drugs has successfully established its presence in multiple African markets, providing high-quality pharmaceutical products. The company’s Mumbai plant is equipped with advanced facilities for dry powder formulations, small-volume liquid ampoules, and vials, making it a key player in global pharmaceutical exports.

With a commitment to quality, innovation, and regulatory excellence, Kilitch Drugs continues to expand its global footprint, reinforcing India’s standing as a leading pharmaceutical exporter.

Driving India’s Pharma Growth

Under Bhavin Mehta’s leadership, Pharmexcil is expected to focus on:

• Enhancing MSME participation in global pharmaceutical exports.
• Expanding market access for Indian pharma products worldwide.
• Strengthening India’s reputation as a leading exporter of generic medicines and specialized pharmaceutical products.

His expertise in strategic expansion and market development will be crucial in guiding Pharmexcil's initiatives to help Indian pharmaceutical companies thrive in competitive international markets.

The Upcoming IPOs in this week and coming weeks are Ken Enterprises, Amwill Healthcare, Readymix Construction, Solarium Green, Eleganz Interiors.

The Current active IPO is Chamunda Electricals.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.

Join our Finance Saathi Telegram Channel for Regular Share Market, News & IPO Updates.